Each year on International Women’s Day, the global community recognizes the achievements of women across industries and disciplines. In biotechnology and pharmaceutical research, women have played a critical role in advancing the science that drives modern medicine, from pioneering discoveries in molecular biology to breakthroughs that enable the development of life-saving therapeutics.
Within the field of antibody drug discovery, women scientists have contributed foundational innovations that shape how researchers identify, engineer, and produce therapeutic antibodies today. As antibody-based medicines continue to transform treatment across oncology, autoimmune diseases, and infectious diseases, it is important to recognize the researchers whose work has helped make these advances possible.
The modern biotechnology revolution has been shaped by remarkable women whose work expanded the possibilities of molecular medicine.
Frances H. Arnold received the Nobel Prize in Chemistry in 2018 for pioneering directed evolution, a technique that allows scientists to engineer proteins by mimicking the process of natural selection in the laboratory. Rather than attempting to design complex proteins from scratch, Arnold’s approach introduces random mutations into a protein’s gene and then screens the resulting variants to identify those with improved or desirable properties. The best-performing variants are selected and subjected to additional rounds of mutation and screening, gradually evolving proteins with enhanced functions.
This method transformed the field of protein engineering because it provides a practical way to optimize biomolecules whose structure–function relationships are often too complex to predict through rational design alone. By harnessing evolutionary principles, researchers can rapidly develop enzymes with improved catalytic activity, stability, or specificity, which are qualities that are essential in biotechnology and pharmaceutical development.
Directed evolution has had a profound impact across many areas of life science. In industrial biotechnology, it has enabled the creation of enzymes that operate efficiently in harsh manufacturing conditions, improving the sustainability of chemical and pharmaceutical production. In medicine, the same principles can be applied to optimize biologics, including therapeutic proteins and antibodies.
For antibody research in particular, directed evolution has helped scientists improve binding affinity, specificity, and stability, all critical factors for developing effective antibody therapeutics. By iteratively evolving antibody variants and selecting those that bind more tightly to their targets, researchers can refine candidate molecules that may eventually become drugs used to treat cancer, autoimmune diseases, and infectious diseases.
Jennifer Doudna is widely recognized for her groundbreaking work in developing CRISPR-Cas9 gene editing, a technology that has fundamentally transformed modern molecular biology. In 2020, she was awarded the Nobel Prize in Chemistry for her role in demonstrating how CRISPR-Cas9 can be programmed to cut DNA at specific locations within a genome.
CRISPR technology originated from a natural defense mechanism found in bacteria, which use CRISPR-associated proteins to recognize and cut viral DNA. Doudna and her collaborators discovered how this system could be adapted into a programmable tool for genome editing. By designing a short piece of guide RNA that matches a target DNA sequence, researchers can direct the Cas9 enzyme to precisely cut DNA at a chosen site. Once the DNA is cut, cellular repair mechanisms can be used to introduce targeted genetic modifications.
Compared to earlier genome-editing methods, CRISPR dramatically reduced the time and cost required to modify genes in living cells and organisms. As a result, it has accelerated research across fields ranging from genetics and agriculture to biotechnology and drug development.
In biomedical research, CRISPR technology allows scientists to create highly accurate cell and animal models of disease, enabling deeper understanding of disease mechanisms and more efficient testing of potential therapeutics. It has also opened new possibilities for gene-based treatments, where faulty genes can potentially be corrected directly within patient cells.
Beyond gene therapy, CRISPR tools have also supported the development of advanced biological platforms used in therapeutic discovery. Researchers can engineer cell lines with specific mutations, modify immune cells for research, and optimize biological systems used in the development of biologics, including antibodies and other protein therapeutics.
Katalin Karikó is widely recognized for her pioneering work in the development of messenger RNA (mRNA) technology, which laid the scientific foundation for the rapid development of vaccines during the global response to COVID-19. Her decades-long dedication to RNA research ultimately helped enable a new class of medicines that are now transforming vaccine development and therapeutic design.
In cells, mRNA acts as a molecular messenger, carrying genetic instructions from DNA to the cellular machinery that produces proteins. Scientists had long envisioned using synthetic mRNA to instruct cells to produce beneficial proteins, such as vaccine antigens or therapeutic molecules, but early research faced major challenges. Synthetic mRNA introduced into the body often triggered strong immune reactions and degraded quickly, making it difficult to use as a stable therapeutic platform.
Karikó’s research focused on overcoming these barriers. Working with collaborators, she discovered that modifying specific nucleosides within mRNA molecules could reduce unwanted immune responses while improving the molecule’s stability and translation efficiency. These insights made it possible to safely deliver mRNA into human cells so that they could produce target proteins effectively.
This breakthrough became the key technological advance that allowed researchers to design mRNA-based vaccines, in which cells are temporarily instructed to produce a harmless viral protein that stimulates the immune system. When the COVID-19 pandemic emerged, scientists were able to rapidly design vaccines using this platform because the underlying technology had already been developed through years of foundational research.
Although their discoveries span multiple fields, the technologies developed by these scientists have significantly influenced modern biologics research, including antibody engineering, therapeutic development, and advanced biomedical tools.
Despite the growing presence of women in STEM education, gender disparities remain in leadership roles across scientific research and biotechnology. According to UNESCO, women represent only 35% of STEM graduates. Encouraging greater participation and visibility for women in science is not only a matter of equity, it also strengthens the innovation ecosystem.
Research has consistently shown that diverse scientific teams produce more creative solutions and impactful discoveries. In fields such as antibody drug discovery, where complex biological challenges require multidisciplinary expertise, inclusive environments help drive more effective collaboration and breakthroughs.
The Fourth Industrial Revolution is rapidly transforming how we work, innovate, and solve global challenges. However, realizing its full potential will require empowering more people with the skills and opportunities needed to participate in the future economy. Closing the gender gap in STEM is a critical part of this effort. Women remain significantly underrepresented in many high-growth technical fields despite evidence that gender-diverse teams drive stronger innovation and economic performance. Expanding access to STEM education, mentorship, and reskilling opportunities can help ensure that women are fully included in shaping the technologies and scientific breakthroughs that will define the next generation of global progress.
Mentorship, visibility, and institutional support are critical factors that help ensure the next generation of women scientists can thrive in biotechnology and pharmaceutical research.
Organizations across the biotech ecosystem, from universities to research institutions and CROs, play an important role in supporting women in science. Key initiatives may include:
Mentorship and career development programs
Inclusive hiring and leadership opportunities
Supporting early-career researchers through training and collaboration
Highlighting the contributions of women scientists within research teams
Through the Biointron Travel Grant Program, we aim to help emerging scientists share their work, build international collaborations, and gain exposure within the global antibody research community. By providing financial support for conference participation, we hope to empower the next generation of researchers to exchange ideas, expand their professional networks, and continue advancing discoveries that may shape the future of antibody therapeutics.
The future of antibody therapeutics will rely on continued collaboration between scientists, engineers, and innovators around the world. As the biotechnology field evolves, recognizing the achievements of women researchers helps highlight the diverse talent driving progress in medicine.
On International Women’s Day, Biointron celebrates the scientists whose work continues to shape the future of biologics research and antibody discovery, today and for generations to come.
Biointron’s Networking Lunch (At the Table: Antibody Discovery) was held at Cata……
AACR Immuno-Oncology Conference (AACR IO) 2026 was held in Los Angeles from Feb……
Bispecific antibodies (bsAbs) are engineered molecules capable of simultaneously……
ScientistとScience Exchangeとのご利用可能です。
